臨床眼科60巻2号

2006年02月発行

特集 どこまで進んだ 分子病態の解明と標的治療

ヘルペス性角膜炎

著者： 井上幸次¹

所属機関： ¹鳥取大学医学部視覚病態学教室

ページ範囲：P.124 - P.129

はじめに

　感染症は原因が外界から来た微生物であることが明確であり，古くから，病因となっている微生物に対していわば「標的治療」をしてきたわけであるから，「どこまで進んだ」といわれても，「標的治療なんて昔からやっている」と簡単に答えてしまいそうである。しかし，感染が生じる機構や感染によって生じる炎症の「分子病態」については，微生物側の因子，ホスト側の因子，その他の環境などの因子の3つが複雑にからみ合っているために，他の疾患，例えばホスト側の因子のみで起こる遺伝子病に比べてその機構はきわめて複雑であり，「どこまで進んだ」といわれると，逆に「まだまだこれからであまり進んでいない」ということになる。まして，「分子病態に基づく標的治療」となると，「海のものとも山のものともつかない」という状況だが，ともあれ，本稿では分子病態の研究がさかんなヘルペス性角膜炎を題材に，分子病態と標的治療の最近の動向についてレビューしてみたい。

参考文献

1）Lillycrop KA, Estridge JK, Latchman DS：The octamer binding protein Oct-2 inhibits transactivation of the herpes simplex immediate-early genes by the virion protein Vmw65. Virology　196：888-891, 1993

T cells are selectively activated and retained in latently infected sensory ganglia. Immunity　18：593-603, 2003

3）Hill JM, Lukiw WJ, Gebhardt BM et al：Gene expression analyzed by microarrays in HSV-1 latent mouse trigeminal ganglion following heat stress. Virus Genes　23：273-280, 2001

4）Higaki S, Gebhardt BM, Lukiw WJ et al：Effect of immunosuppression on gene expression in the HSV-1 latently infected mouse trigeminal ganglion. Invest Ophthalmol Vis Sci　43：1862-1869, 2002

5）Hendricks RL, Tumpey TM, Finnegan A：IFN-γand IL-2 are protective in the skin but pathologic in the corneas of HSV-1-infected mice. J Immunol 149：3023-3028, 1992

6）Kanangat S, Thomas J, Gangappa S et al：Herpes simplex virus type-1mediated up-regulation of IL-12（p40）mRNA expression. J Immunol　156：1110-1116, 1996

7）Yoshida A, Miyazaki D, Inoue Y et al：The relation between cytokines released from peripheral blood T cells and recurrences in herpetic keratitis patients. Invest Ophthalmol Vis Sci　41：S56, 2000

8）Babu JS, Kanangat S, Rouse BT：T cell cytokine mRNA expression during the course of the immunopathologic ocular disease herpetic stromal keratitis. J Immunol　154：4822-4829, 1995

9）Daheshia M, Kuklin N, Kanangat S et al：Suppression of ongoing ocular inflammatory disease by topical administration of plasmid DNA encoding IL-10. J Immunol　159：1945-1952, 1997

10）Staats HF, Lausch RN：Cytokine expression in vivo during murine herpetic stromal keratitis. J Immunol　151：277-283, 1993

11）Biswas PS, Banerjee K, Kim B et al：Mice transgenic for IL-1 receptor antagonist protein are resistant to herpetic stromal keratitis：possible role for IL-1 in herpetic stromal keratitis pathogenesis. J Immunol　172：3736-3744, 2004

12）Fenton RR, Molesworth-Kenyon S, Oakes JE et al：Linkage of IL-6 with neutrophil chemoattractant expression in virus-induced ocular inflammation. Invest Ophthalmol Vis Sci　43：737-743, 2002

13）Wasmuth S, Bauer D, Yang Y et al：Topical treatment with antisense oligonucleotides targeting tumor necrosis factor-αin herpetic stromal keratitis. Invest Ophthalmol Vis Sci　44：5228-5234, 2003

14）Kumaraguru U, Davis I, Rouse BT：Chemokines and ocular pathology caused by corneal infection with herpes simplex virus. J Neurovirol　5：42-47, 1999

15）Tumpey TM, Cheng H, Yan XT et al：Chemokine synthesis in the HSV-1-infected cornea and its suppression by interleukin-10. J Leukoc Biol　63：486-492, 1998

16）Yan XT, Tumpey TM, Kunkel SL et al：Role of MIP-2 in neutrophil migration and tissue injury in the herpes simplex virus-1-infected cornea. Invest Ophthalmol Vis Sci　39：1854-1862, 1998

17）Tumpey TM, Cheng H, Cook DN et al：Absence of macrophage inflammatory protein-1αprevents the development of blinding herpes stromal keratitis. J Virol　72：3705-3710, 1998

18）Miyazaki D, Inoue Y, Araki-Sasaki K et al：Neutrophil chemotaxis induced by corneal epithelial cells after herpes simplex virus type 1 infection. Curr Eye Res　17：687-693, 1998

19）Zheng M, Klinman DM, Gierynska M et al：DNA containing CpG motifs induces angiogenesis. PNAS 99：8944-8949, 2002

20）Zheng M, Deshpande S, Lee S et al：Contribution of vascular endothelial growth factor in the neovascularization process during the pathogenesis of herpetic stromal keratitis. J Virol　75：9828-9835, 2001

21）Kim B, Tang Q, Biswas PS et al：Inhibition of ocular angiogenesis by siRNA targeting vascular endothelial growth factor pathway genes. Am J Pathol 165：2177-2185, 2004

22）Chen H, Hendricks RL：B7 costimulatory requirements of T cells at an inflammatory site. J Immunol 160：5045-5052, 1998

23）Gangappa S, Manickan E, Rouse BT：Control of herpetic stromal keratitis using CTLA41g fusion protein. Clin Immunol Immunopathol　86：88-94, 1998

24）Seo SK, Park HY, Choi JH et al：Blocking 4-1BB/4-1 BB ligand interactions prevents herpetic stromal keratitis. J Immunol　171：576-583, 2003

25）Yang YN, Bauer D, Wasmuth S et al：Matrix metalloproteinases（MMP-2 and 9）and tissue inhibitors of matrix metalloproteinases（TIMP-1 and 2）during the course of experimental necrotizing herpetic keratitis. Exp Eye Res　77：227-237, 2003

26）Biswas PS, Banerjee K, Kim B et al：Role of inflammatory cytokine-induced cycloxygenase 2 in the ocular immunopathologic disease herpetic stromal keratitis. J Virol　79：10589-10600, 2005

27）Avery AC, Zhao ZS, Rodriguez A et al：Resistance to herpes stromal keratitis conferred by an IgG2a-derived peptide. Nature　376：431-434, 1995

28）Zhao ZS, Granucci F, Yeh L et al：Molecular mimicry by herpes simplex virus-type 1：autoimmune disease after viral infection. Sciecnce　279：1344-1347, 1998

29）Deshpande SP, Lee S, Zheng M et al：Herpes simplex virus-induced keratitis：evaluation of the role of molecular mimicry in lesion pathogenesis. J Virol 75：3077-3088, 2001

T cells accounts for herpetic ocular lesions. Invest Ophthalmol Vis Sci　41：453-459, 2000

31）Inoue T, Inoue Y, Nakamura T et al：Preventive effect of local plasmid DNA vaccine encoding gD（HSV-1）or gD-IL-2 on herpetic keratitis. Invest Ophthalmol Vis Sci　41：4209-4215, 2000

32）Inoue T, Inoue Y, Hayashi K et al：Topical administration of HSV gD-IL-2 DNA is highly protective against murine herpetic stromal keratitis. Cornea 21：106-110, 2002

T-cells in exacerbation of corneal scarring in mice. Cur Eye Res　29：145-151, 2004

34）Kuklin N, Daheshia M, Karem K et al：Induction of mucosal immunity against herpes simplex virus by plasmid DNA immunization. J Virol　71：3138-3145, 1997

35）Richards CM, Case R, Hirst TR et al：Protection against recurrent ocular herpes simplex virus type 1 disease after therapeutic vaccination of latently infected mice. J Virol　77：6692-6699, 2003